New hope for rare vasculitis: obinutuzumab steps in where rituximab fails
NCT ID NCT07268521
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests obinutuzumab, a drug similar to rituximab but possibly stronger, in 30 adults with active cryoglobulinemic vasculitis who did not improve or could not tolerate rituximab. The goal is to see if obinutuzumab can bring the disease under control and allow patients to stop steroids. It is a small, early study to check if the drug works and is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- obinutuzumab
- What this could lead to
- If it works, this could offer a new treatment option for people with cryoglobulinemic vasculitis who cannot use rituximab.
- What could go wrong
- This is a small, early-phase trial with only 30 participants. It may not show clear benefit, and obinutuzumab could cause side effects like infusion reactions or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRYOGLOBULINEMIC VASCULITIS (CV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.